Immuneering Corporation

NASDAQ:IMRX

1.93 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 00-94.419094.419000.0380.0940.1840.190.4820.660.7480.6650.6830.4810.483
Cost of Revenue 0.1750.1880.1850.1960.1940.19157.9640.0190.0480.0910.2060.2190.3190.4090.4730.3150.2370.255
Gross Profit -0.175-0.188-94.604-0.19694.225-0.19-157.9630.0190.0460.093-0.0170.2630.3410.3390.1920.3680.2440.228
Gross Profit Ratio 001.00200.9980-346,411.0130.4960.4920.505-0.0880.5460.5170.4530.2880.5390.5070.472
Reseach & Development Expenses 10.5911.14111.9110.059.45310.2119.8729.3647.9819.0597.956.2076.9925.3914.894.0693.2212.823
General & Administrative Expenses 4.2544.1164.3853.8694.0454.4614.1063.8363.7043.9523.1492.5991.341.1841.1380.6990.6290.644
Selling & Marketing Expenses -4,250.325-0.1190000000000000000
SG&A 4.1483.9974.3853.8694.0454.4614.1063.8363.7043.9523.1492.5991.341.1841.1380.6990.6290.644
Other Expenses 0.0080.2130.4640.0070.150.0070.0070.007-0.0240.008-0.119-0.008000000
Operating Expenses 14.73815.13816.30313.92613.50514.67913.98513.20711.69213.01911.0998.8068.3326.5756.0284.7683.853.467
Operating Income -14.914-15.326-16.302-13.926-13.505-14.68-13.985-13.188-11.646-12.926-11.116-8.543-7.991-6.236-5.836-4.4-3.607-3.239
Operating Income Ratio 000.1730-0.1430-30,668.875-343.62-123.344-70.364-58.63-17.72-12.107-8.335-8.776-6.447-7.501-6.706
Total Other Income Expenses Net 0.8341.0180.4641.3310.151.0760.7390.344-0.0240.029-0.119-0.0080.0040.00600.0010.0030.038
Income Before Tax -14.08-14.308-15.084-12.595-12.189-13.604-13.246-12.844-11.527-12.897-11.092-8.534-7.987-6.23-5.836-4.399-3.604-3.201
Income Before Tax Ratio 000.160-0.1290-29,047.285-334.661-122.085-70.205-58.504-17.701-12.101-8.326-8.775-6.445-7.495-6.626
Income Tax Expense -0-0-0.755-13,912.372-1.139-1,075.403-0.74-0.344-0.052-0.029-0.307-0.0170.00100.042-00.0010
Net Income -14.08-14.308-15.083-12.595-12.1891,061.799-12.506-12.501-11.527-12.867-10.784-8.534-7.988-6.23-5.836-4.399-3.604-3.201
Net Income Ratio 000.160-0.1290-27,424.346-325.704-122.087-70.045-56.882-17.701-12.102-8.326-8.775-6.445-7.496-6.626
EPS -0.47-0.49-0.52-0.43-0.4340.16-0.47-0.47-0.44-0.49-0.42-0.47-0.33-0.46-0.43-0.33-0.27-0.24
EPS Diluted -0.47-0.49-0.52-0.43-0.4340.16-0.47-0.47-0.44-0.49-0.42-0.47-0.33-0.46-0.43-0.33-0.27-0.24
EBITDA -14.738-15.138-16.205-13,926.338-13.498-14.49-13.978-12.984-11.639-12.725-11.116-8.506-7.955-6.202-5.762-4.385-3.59-3.224
EBITDA Ratio 000.1720-0.1430-30,652.829-338.29-123.265-69.272-58.63-17.642-12.053-8.289-8.663-6.424-7.467-6.674